Latvia
Tuberculosis profile
| High MDR-TB burden |
Population  2013 2.1 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.043 (0.043–0.043) 2.1 (2.1–2.1)
Mortality (HIV+TB only) 0.036 (0.028–0.045) 1.8 (1.4–2.2)
Prevalence  (includes HIV+TB) 1.2 (0.57–2) 58 (28–100)
Incidence  (includes HIV+TB) 1 (0.96–1.1) 50 (47–54)
Incidence (HIV+TB only) 0.2 (0.19–0.22) 10 (9.3–11)
Case detection, all forms (%) 85 (79–91)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 8.8 (6.6–12) 26 (18–35)
MDR-TB cases among notified pulmonary
TB cases
61 (45–80) 31 (21–42)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 573   80
Pulmonary, clinically diagnosed 118   7
Extrapulmonary 85   9
       
Total new and relapse 872    
Previously treated, excluding relapses 32    
Total cases notified 904    
Among 872 new and relapse cases:
45 (5%) cases aged under 15 years; male:female ratio: 2.0
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 572 (100%) 109 (85%) 681
Laboratory-confirmed RR-/MDR-TB cases     82
Patients started on MDR-TB treatment     79
TB/HIV 2013 Number (%)
TB patients with known HIV status 478 (53)
HIV-positive TB patients 95 (20)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 39 (41)
HIV-positive TB patients on antiretroviral therapy (ART) 47 (49)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 87
Previously treated cases, excluding relapse, registered in 2012 50
HIV-positive TB cases, all types, registered in 2012 78
RR-/MDR-TB cases started on second-line treatment in 2011 55
XDR-TB cases started on second-line treatment in 2011 42
Laboratories 2013  
Smear (per 100 000 population) 0.8
Culture (per 5 million population) 9.9
Drug susceptibility testing (per 5 million population) 2.5
Sites performing Xpert MTB/RIF 2
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 2.3
% Funded domestically 96%
% Funded internationally 0%
% Unfunded 4%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-08-31 Data: www.who.int/tb/data